Drug profile · INN
arimoclomol citrate
MIPLYFFA
arimoclomol citrate (MIPLYFFA) is a unknown. Associated with ZEVRA THERAPEUTICS, INC.. Route of administration: oral. Current US regulatory status: approved.
Drug details — arimoclomol citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 0
- Data quality
- 0.89
Quick answer
arimoclomol citrate (MIPLYFFA) is a unknown. Associated with ZEVRA THERAPEUTICS, INC.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Unknown
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related patents
-
US 12251445
Gamma-hydroxybutyrate delivering compounds and processes for making and using them
granted -
US 12076316
Levorphanol prodrugs and processes for making and using them
granted -
US 12012384
Dextrorphan prodrugs and processes for making and using them
granted -
US 11938125
Use of Hsp70 as a regulator of enzymatic activity
granted
Frequently asked questions
What is arimoclomol citrate?
arimoclomol citrate (MIPLYFFA) is a unknown. Associated with ZEVRA THERAPEUTICS, INC.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for arimoclomol citrate?
MIPLYFFA is a marketed brand name for arimoclomol citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of arimoclomol citrate?
arimoclomol citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.